Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Hematology/ Oncology and Stem Cell Therapy is Scopus-indexed (Q2, CiteScore 4.2), DOAJ. Published by Wolters Kluwer Health.
Checked against the index lists dated .
ISSN 1658-3876Verify ISSN ↗2589-0646Verify ISSN ↗
Publisher: Wolters Kluwer Health
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 53 / 151 | 65th | Q2 |
| Oncology | 207 / 428 | 51st | Q2 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2008–present, best quartile Q2, CiteScore 4.2.
Hematology/ Oncology and Stem Cell Therapy is Q2 in Hematology (rank 53 of 151) and Q2 in Oncology (rank 207 of 428), by CiteScore 2025.
Hematology/ Oncology and Stem Cell Therapy is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 4.2, quartile Q2, 65th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.506, quartile Q3, with an H-index of 34.
Hematology/ Oncology and Stem Cell Therapy is published by Wolters Kluwer Health. Its print ISSN is 1658-3876 and its online ISSN is 2589-0646.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Hematology/ Oncology and Stem Cell Therapy has an h-index of 40 and a 2-year mean of 1 citations per paper (OpenAlex). Its Scopus CiteScore is 4.2, quartile Q2. On 2-year citations it ranks #91 of 148 Scopus journals in Hematology.
Hematology/ Oncology and Stem Cell Therapy published 22 papers in 2025; its busiest recent year was 2020 with 83. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2021–2026), authors are most often from United States (36.1%), Saudi Arabia (22.5%) and Egypt (5.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (2.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.